ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP) — ELEVATE

Acute Hepatic Porphyria Clinical Trial

Official title:
ELEVATE, a Global Observational Longitudinal Prospective Registry of Patients With Acute Hepatic Porphyria (AHP)

Status Recruiting

Clinical Trial Summary

This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04883905
Study type	Observational
Source	Alnylam Pharmaceuticals
Contact	Alnylam Clinical Trial Information Line
Phone	1-877-ALNYLAM
Email	clinicaltrials@alnylam.com
Status	Recruiting
Phase
Start date	April 26, 2021
Completion date	April 2027

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03338816` - ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)	Phase 3
Terminated	`NCT03547297` - INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHP
Not yet recruiting	`NCT04923516` - Prevalence of Acute Hepatic Porphyria
Recruiting	`NCT05344599` - Evaluating the Prevalence of Acute Hepatic Porphyria in Postural Tachycardia Syndrome
Completed	`NCT02240784` - EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)
Approved for marketing	`NCT04056481` - Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria